210345-04-3
中文名稱
CS-1506
英文名稱
Z-LEHD-FMK
CAS
210345-04-3
分子式
C32H43FN6O10
分子量
690.73
MOL 文件
210345-04-3.mol
更新日期
2026/05/28 12:19:27
210345-04-3 結(jié)構(gòu)式
基本信息
英文別名
CS-1506Z-LEHD-FMK
CASPASE-9 INHIBITOR
Z-LE(OME)HD(OME)-FMK
CASPASE-9 INHIBITOR I
Z-LEHD-FLUOROMETHYLKETONE
Z-LEU-GLU(OME)-HIS-ASP(OME)-FMK
Z-LE(OME)HD(OME)-FLUOROMETHYLKETONE
Z-LEU-GLU-HIS-ASP-FLUOROMETHYLKETONE
CASPASE-9 INHIBITOR (FLUOROMETHYLKETONE)
物理化學(xué)性質(zhì)
沸點(diǎn)1008.2±65.0 °C(Predicted)
密度1.272±0.06 g/cm3(Predicted)
儲(chǔ)存條件-20°C
溶解度溶于二甲基亞砜。
酸度系數(shù)(pKa)11.11±0.46(Predicted)
形態(tài)powder
顏色White to yellow
InChIKeyYXRKBEPGVHOXSV-PPPRLRNRNA-N
SMILES[C@H](C(=O)N[C@H](C(=O)CF)CC(=O)OC)(NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1C=CC=CC=1)CC1N=CNC=1 |&1:0,4,17,27,r|
CS-1506價(jià)格(試劑級)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-P1010 | CS-1506 Z-LEHD-FMK | 210345-04-3 | 1mg | 2500元 |
| 2026/06/05 | HY-P1010 | Z-LEHD-FMK | 210345-04-3 | 5 mg | 6000元 |
常見問題列表
生物活性
Z-LEHD-FMK 是一種選擇性和不可逆的 caspase-9 抑制劑，可防止致命的再灌注損傷并減弱細(xì)胞凋亡。Z-LEHD-FMK 在大鼠脊髓損傷模型中也表現(xiàn)出神經(jīng)保護(hù)作用。靶點(diǎn)
|
Caspase-9
|
體外研究
Z-LEHD-FMK (20 μM; pretreated for 30 min) completely protects HCT116 and 293 cells from TRAIL-induced toxicity.
Z-LEHD-FMK (20 μM ; 6 h) protects normal human hepatocytes from TRAIL-induced apoptosis.
Apoptosis Analysis
| Cell Line: | SW480, H460, HCT116 and 293 cells |
| Concentration: | 20 μM |
| Incubation Time: | Pretreated for 30 min |
| Result: | Protected HCT116 and 293 cells from TRAIL-induced apoptosis. |
Western Blot Analysis
| Cell Line: | HCT116, SW480 cells |
| Concentration: | 20 μM |
| Incubation Time: | 2 h |
| Result: | Protected procaspase 3 from cleavage in HCT116 cells but not in SW480 cells, especially at the 16-h time point. |
體內(nèi)研究
Z-LEHD-FMK (0.8 μmol/kg; i.v. for 7 d) protects neurons, glia, myelin, axons, and intracellular organelles in spinal cord injury (SCI) rats.
| Animal Model: | Male Wistar albino rats (250-350 g) with SCI |
| Dosage: | 0.8 μmol/kg |
| Administration: | I.v. for 1 or 7 days |
| Result: | Decreased the mean apoptotic cell count at 24 hours and 7 days postinjury. |